- Conditions
- Advanced Pancreatic Cancer, Solid Tumor Malignancies
- Interventions
- ProAgio Dose Levels (DL) 1,2,3, ProAgio Dose Levels (DL) 4,5,6, ProAgio Dose Levels 4a,5a,6a
- Drug
- Lead sponsor
- ProDa BioTech, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 14,388
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
- Interventions
- RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
- Conditions
- Medication Overuse Headache
- Interventions
- DFN-11 Injection
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Stress Hyperglycemia
- Interventions
- Dulaglutide Injection, Saline Injection
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Interventions
- nab-Sirolimus, Fulvestrant
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
- Drug
- Lead sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
- Interventions
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
- Interventions
- 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
- Drug
- Lead sponsor
- Nymox Corporation
- Industry
- Eligibility
- 45 Years to 75 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- Diabetic Neuropathy
- Interventions
- VEGF
- Biological
- Lead sponsor
- Losordo, Douglas, M.D.
- Individual
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
- Conditions
- Kidney Transplantation, Chronic Kidney Failure
- Interventions
- efalizumab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- SAR408701, ramucirumab, pembrolizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Buffalo, New York • Waco, Texas
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
- Biological
- Lead sponsor
- COL George Peoples, MD, FACS
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Macular Degeneration
- Interventions
- intravitreal injection Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Neoplasms by Histologic Type, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Disorder
- Interventions
- lisocabtagene maraleucel
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 20 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
- Conditions
- Invasive Breast Cancer
- Interventions
- PVSRIPO
- Biological
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neisseria Gonorrhoeae Infection
- Interventions
- Meningococcal Group B Vaccine
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Post-Operative Pain
- Interventions
- VVZ-149 Injections, Placebo
- Drug
- Lead sponsor
- Vivozon, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Lispro Insulin and glargine insulin
- Drug
- Lead sponsor
- Diabetes Care Center
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Salinas, California
- Conditions
- Macular Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Abscess
- Interventions
- Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage
- Drug · Device · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Rochester, New York
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Interventions
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
- Biological · Drug · Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy, Premature Ovarian Failure
- Interventions
- Control, Drug: FSH
- Other · Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland